Therapeutic Targets Database
BIDD Pharmainformatics Databases


Target Validation Information
Target NameGastrin-releasing peptide receptor    
Type of TargetClinical trial target    
Drug Potency against Target[N40,Pro1,Tyr4]BBIC50 = 0.06 nM[1]
[(N4-Bzdig)0]BB(7-14)IC50 = 0.08 nM[1]
[N40,Pro1,Tyr4,Nle 14]BBIC50 = 0.15 nM[1]
[(N4-Bzdig)0,Nle14]BB(7-14)IC50 = 0.6 nM[1]
Universal ligandIC50 = 0.72 nM[1]
[Tyr4]BombesinIC50 = 0.85 nM[1]
Ac-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2IC50 = 1.8 nM[2]
Ac-His-Trp-Ala-Val-Ala-His-Leu-Met-NH2IC50 = 180 nM[2]
Ac-His-Trp-Ala-Val-D-Ala-His-Leu-Met-NH2IC50 = 3.2 nM[2]
(CH3)CCO-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2IC50 = 4.1 nM[2]
JMV 1802Ki = 0.8 nM[3]
JMV 1535Ki = 1 nM[3]
JMV 1799Ki = 1.2 nM[3]
JMV 1719Ki = 11 nM[3]
JMV 1801Ki = 2 nM[3]
JMV 1803Ki = 2 nM[3]
JMV 1813Ki = 2 nM[3]
JMV 1693Ki = 53 nM[3]
(D)Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2Ki = 6.3 nM[3]
Action against Disease ModelRC-3095RC-3095 at 1 nM concentration effectively inhibited the bombesin-stimulated growth of CFPAC-1 cells in cultures. In the presence of 1 microM RC-3095 in the culture medi uM, the bombesin-induced growth of CFPAC-1 cells was totally suppressed.[4]
The Effect of Target Knockout, Knockdown or Genetic VariationsPharmacologic/receptor-knockout studies show involvement of these receptors in a n uMber of new processes/diseases. Neuromedin B/BB1-receptor is an important physiological regulator of pituitary-thyroid function; in mediating behavior, especially feas/anxiety; in mediating satiety through different cascades than gastrin-releasing peptide/BB2 receptors and for its autocrine t uMor-growth effects. Gastrin-releasing peptide/BB2-receptor plays important roles in mediating signals for pruritus, lung development/injury, small intestinal mucosal defense, and central nervous system processes such as learning/memory. The signaling mechanisms of its potent growth effects are being elucidated and their possible therapeutic targets identified. BB3-receptor knockout mice provided insights for their obesity/glucose intolerance and demonstrated that this receptor may be important in the lung response to injury, t uMor growth and gastrointestinal motility. Each receptor is frequently overexpressed in h uMan t uMors and has potent growth effects. This effect is being explored to develop new antit uMor treatments, such as bombesin-receptor ligands conjugated to cytotoxic agents.[5]
Ref 1J Med Chem. 2005 Jan 13;48(1):100-10.Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. To Reference
Ref 2J Med Chem. 1991 Jul;34(7):2102-7.Gastrin releasing peptide antagonists with improved potency and stability. To Reference
Ref 3J Med Chem. 2000 Jun 15;43(12):2356-61.Synthesis and biological evaluation of bombesin constrained analogues. To Reference
Ref 4Oncogene. 2005 Aug 4;24(33):5262-8.Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. To Reference
Ref 5Curr Opin Endocrinol Diabetes Obes. 2008 Feb;15(1):58-64.Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543